Halozyme Therapeutics (HALO) Raised to $19 at Piper Jaffray

March 3, 2015 7:17 AM

Piper Jaffray analyst Charles Duncan reiterated an Overweight rating and boosted his price target on Halozyme Therapeutics (NASDAQ: HALO) to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found